Can shareholder rights law firm investigations pressure Hims & Hers Health stock?

Traders Union
All News
Stocks
Hims & Hers Health slides 4% today

Highlights

The Federal Trade Commission filed a lawsuit against Hims & Hers Health alleging improper sharing of customer medical data with advertisers.
Shareholder rights law firms launched investigations into possible federal securities law violations, increasing legal and compliance risks for the company.
HIMS/USD trades below key moving averages with persistent selling pressure, negative momentum signals, and a projected short-term range of $27.12 to $30.42.

Compliance scrutiny intensifies after FTC lawsuit prompts legal probe

Hims & Hers Health, Inc. was named in a lawsuit filed by the Federal Trade Commission on July 29, 2026, accusing the company of sharing customers' medical information with third-party advertisers. This regulatory action increased legal exposure and raised concerns over data privacy practices. In the wake of the FTC lawsuit, several shareholder rights law firms announced investigations into potential violations of federal securities laws, further highlighting compliance risks for Hims & Hers Health, according to Globenewswire.

Broad technical weakness as oversold signals reinforce resistance

On the technical side, HIMS trades below its MA-20 at $29.96 and MA-50 at $30.72 on the hourly chart, and also remains under the MA-200 at $29.37 on the daily timeframe. Immediate resistance is marked by the Ichimoku Kijun at $30.31, while the nearest support is at $27.12. Momentum indicators show persistent weakness with the MACD and ADX both signaling sell, the RSI deep in the oversold territory at 34.17, and both Stoch RSI and CCI confirming oversold conditions. Bearish bias is further supported by negative Bull/Bear Power, and the Awesome Oscillator also aligns with the overall downtrend.

Volatility expected to persist as price tests resistance and support

Over the next two to three trading days, HIMS is expected to fluctuate within a volatility band between $27.12 and $30.42. Upside potential is minimal unless price manages to break above the $30.31 resistance, creating room for a rebound. A move below $27.12 would point to further short-term downside. The baseline scenario sees price action staying within this corridor under high volatility.

Anton Kharitonov, expert at Traders Union, views Hims & Hers Health as facing heightened uncertainty. He notes that regulatory and legal risks have intensified after the FTC lawsuit, with price action confirming persistent selling pressure. Key technicals remain bearish and sentiment is fragile. "I stay defensive here — the downtrend holds as long as HIMS trades below $30.31."

Earlier, analysts noted that long-term growth opportunities for Hims & Hers Health hinge on strategic product expansion, but that near-term impacts would likely be modest amid regulatory uncertainties. The current technical and legal pressures introduce fresh risks to the stock’s outlook, making sustained movement above the $30.31 resistance a crucial signal for any potential reversal.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.